Propafenone Hydrochloride (Rythmol) is a class Ic antiarrhythmic agent primarily used to prolong the time to recurrence of symptomatic atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT), and to treat life-threatening ventricular arrhythmias.
I. Dosage and Administration Guidelines
1. Initiation and Dose Adjustment
(1) Treatment with Propafenone Hydrochloride should be individualized and titrated based on patient response and tolerability.
(2) The recommended starting dose is 150 mg orally every 8 hours (i.e., total daily dose of 450 mg).
(3) If further efficacy is needed, the dose may be increased to 225 mg to 300 mg every 8 hours (i.e., total daily dose of 675 mg to 900 mg) after at least 3 to 4 days of dosing.
(4) The safety and effectiveness of daily doses exceeding 900 mg have not been established.
2. Dosage Considerations for Special Populations
(1) For patients with hepatic impairment, or those experiencing marked widening of the QRS complex or second- or third-degree atrioventricular block, dose reduction should be considered.
(2) Elderly patients or those with a history of significant myocardial damage presenting with ventricular arrhythmias should have the dose increased more slowly during the initial treatment phase.
II. Important Safety Precautions
1. Contraindications and Warnings
(1) Propafenone Hydrochloride is contraindicated in patients with: heart failure, cardiogenic shock, existing sinus node, atrioventricular nodal, or intraventricular conduction disorders (e.g., sick sinus syndrome, atrioventricular block) without a pacemaker, known Brugada syndrome, bradycardia, marked hypotension, bronchospastic disorders or severe obstructive pulmonary disease, and significant electrolyte imbalances.
(2) This drug carries a risk of proarrhythmia, which may induce new arrhythmias or worsen existing arrhythmias, potentially leading to sudden death.
(3) Therefore, electrocardiographic monitoring and evaluation are mandatory before and during treatment.
2. Drug Interactions
(1) The metabolism of Propafenone Hydrochloride involves isoenzymes CYP2D6, CYP3A4, and CYP1A2.
(2) Concomitant use of CYP2D6 inhibitors (e.g., paroxetine, sertraline) and CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, grapefruit juice) should be avoided, as this combination can significantly increase propafenone plasma concentrations, raising the risk of adverse effects.
(3) Furthermore, this drug increases the plasma levels of digoxin and warfarin. Close monitoring and appropriate dose adjustments are required when coadministered.
(4) Caution is also warranted when used with other drugs that prolong the QT interval (e.g., certain antiarrhythmics, tricyclic antidepressants).
III. Healthy Lifestyle Recommendations for Patients
1. Regular Monitoring and Follow-up
Patients taking Propafenone Hydrochloride must adhere to scheduled follow-up electrocardiograms to monitor the drug's effects on cardiac conduction (e.g., changes in PR interval, QRS duration) and to detect potential proarrhythmic effects in a timely manner.
2. Dietary and Lifestyle Adjustments
(1) Avoid interacting foods/beverages: During treatment, avoid drinking grapefruit juice, as it inhibits the CYP3A4 enzyme and affects drug metabolism.
(2) Maintain a balanced diet: Ensure adequate nutritional intake to prevent electrolyte imbalances caused by severe diarrhea, vomiting, or poor appetite. Inform your doctor promptly if these occur.
(3) Limit stimulants: It is advisable to reduce or avoid caffeine, alcohol, and other substances that may stimulate the heart and trigger rhythm disturbances.
(4) Moderate activity: Engage in regular, mild-to-moderate aerobic exercise (e.g., walking, tai chi) as permitted by the physician's assessment of cardiac function. This helps improve cardiovascular health. Avoid sudden strenuous exercise.
